Our Policy Network
PACE is a collaboration across international borders and among diverse stakeholders-including industry, academia, payers, and patient groups. PACE acts as a network of networks: to create wider awareness of what is being done to speed innovations to the patients who need them, to help coordinate existing work, and to avoid duplication of effort and waste of resources. Our founding research study lays out key policy challenges and maps what already is being done in response. Our Action Plan shares how PACE initially seeks to help. And our Global Council acts as the hub of our network and a source of counsel.
The Cancer Policy Environment, Barriers to Faster Oncology Innovation, and Strategies for Moving Forward
As a society, we still face many difficult barriers in the fight against cancer. The war on cancer simply cannot succeed based on policies established before the new insights on cancer. A continuing overhaul of laws, regulations, and programs governing the research, development, regulation, evaluation, and uptake of cancer treatments today is vital. This discussion paper is meant to provide an overview of the cancer policy terrain and to encourage readers to focus on common challenges regardless of geography, culture, or profession.
PACE Action Plan
PACE is committed to encouraging public policies and health care decisions that speed the development of new medicines, assure cancer treatments respond to the needs and qualities of individual patients, and improve patient access to the most effective cancer medicines. Here is our plan for moving forward.
The PACE Global Council brings together a small group of internationally renowned patient advocacy, medical, policy, scientific and health care industry leaders.
The purpose of the Council is:
- to provide a forum for intellectual exchange and for linkage between existing initiatives led by its members;
- to recommend actions consistent with the goals of PACE to devise or encourage policy reforms
- to improve public awareness on cancer-related issues
The Council aims to be fully transparent about its origins, support, and intentions:
- Initial financial support for PACE and the Council originates solely with Lilly Oncology even as future support from other companies or organizations is not excluded.
- Lilly Oncology's interests in PACE are to encourage cross-sector consensus on policy reforms that improve cancer care and treatment, and to preserve an environment in which innovation against cancer can flourish.
- Council participants may be reimbursed by Lilly Oncology at reasonable and customary levels for their time and/or expenses related to Council activities to the extent permitted by law in the relevant jurisdiction and will comply with any transparency requirement. However, a number of participants refuse such reimbursement.
- The Council neither discusses nor influences Lilly Oncology's products or pipeline.
- PACE and the Council do not dispense medical advice or endorse any medical treatments, providers, practices or institutions.
- Council participants do not necessarily endorse the actions, positions, or statements of PACE or Lilly Oncology; nor do PACE and Lilly Oncology necessarily endorse the actions, positions, or statements of Council participants.
In summary: PACE and the participants in the PACE Global Council are mutually independent but come together voluntarily under the shared goal of speeding cancer innovations to the patients who need them.